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Structural insights into antigen 
recognition of an anti-β-(1,6)-β-
(1,3)-D-glucan antibody
Kwang Hoon Sung1, Jörn Josewski  2, Stefan Dübel2, Wulf Blankenfeldt  1,2 & Udo Rau2
Schizophyllan (SCH) is a high molecular weight homopolysaccharide composed of a β-(1,3)-D-glucan 
main chain with branching β-(1,6)-bound D-glucose residues. It forms triple helices that are highly 
stable towards heat and extreme pH, which provides SCH with interesting properties for industrial and 
medical applications. The recombinant anti-SCH antibody JoJ48C11 recognizes SCH and related β-(1,6)-
branched β-(1,3)-D-glucans, but details governing its specificity are not known. Here, we fill this gap by 
determining crystal structures of the antigen binding fragment (Fab) of JoJ48C11 in the apo form and 
in complex with the unbranched β-(1,3)-D-glucose hexamer laminarihexaose 3.0 and 2.4 Å resolution, 
respectively. Together with docking studies, this allowed construction of a JoJ48C11/triple-helical SCH 
complex, leading to the identification of eight amino acid residues of JoJ48C11 (Tyr27H, His35H, Trp47H, 
Trp100H, Asp105H; Asp49L, Lys52L, Trp90L) that contribute to the recognition of glucose units from all 
three chains of the SCH triple helix. The importance of these amino acids was confirmed by mutagenesis 
and ELISA-based analysis. Our work provides an explanation for the specific recognition of triple-helical 
β-(1,6)-branched β-(1,3)-D-glucans by JoJ48C11 and provides another structure example for anti-
carbohydrate antibodies.
Schizophyllan (SCH) is a homopolysaccharide produced by the basidiomycete Schizophyllum commune1. It is 
composed of a β-(1,3)-D-glucan main chain that possesses additional single β-(1,6)-bound D-glucose residues 
at approximately every third monomer of the backbone2–4. The average molecular weight ranges from 6 × 106 
to 1.3 × 107 g moL−1 5,6. In aqueous solution, SCH exists as a trimeric molecule with three twisted glucan chains 
held together by hydrogen bonds and the β-(1,6)-bound D-glucose residues pointing towards the outside6–9. The 
helical secondary structure is stable in a broad pH range and at high temperatures, starting to dissolve into single 
chains only at pH > 12 and above 135 °C9,10. The rigidity of the triplex is considered to be the prime reason for 
the high viscosities of aqueous SCH solutions and their pseudoplastic flow behavior, since its denaturation leads 
to strong reduction of viscosity1,6,9–11. Because of the stable viscosity at high temperatures and high salt concen-
trations, SCH is tested as polymer flooding agent for enhanced oil recovery12,13. Furthermore, SCH has several 
bioactive properties, similar to other fungal β-(1,3)-D-glucans14–18. It shows antitumoral and immunomodulating 
effects which are assumed to be based on the enhancement of cell-mediated immune response19–22.
Because of the potential of SCH in different applications, specific SCH antibodies for quantitative trace analy-
sis or for the investigation of the role of particular conformations for glucan bioactivity are needed. Towards this, 
we have generated recombinant antibodies (rAbs) against SCH by antibody phage display23. Next to SCH, these 
antibodies were identified to bind also to other similar β-(1,6)-branched β-(1,3)-D-glucans like scleroglucan and 
cinerean24–26. Further specificity profiling indicated the triple helical structure with the protruding β-(1,6)-linked 
D-glucose as a crucial factor for binding. Denaturation of the secondary structure resulted in a sharp decrease 
of binding affinity and no binding was detected for β-(1,6)-D-gentiobiose and laminarihexaose representing the 
β-(1,6)-branches and β-(1,3)-backbone. For validation of the hypothesis that the secondary structure of SCH is 
indeed important for recognition, structure analysis of the antibody paratope would be required to develop a 
structural model that describes the interaction with SCH and related molecules.
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Here, we have determined the crystal structure of the antigen binding fragment (Fab) of anti-SCH antibody 
JoJ48C11, both in the apo form and in complex with the oligosaccharide laminarihexaose. These structures allow 
modelling of an antibody/SCH complex which suggests that all three chains of the helical glucan engage in inter-
actions with the paratope of JoJ48C11. Importantly, these interactions involve several protruding β-(1,6)-bound 
glucose residues of SCH, explaining the specificity of the antibody. The model was validated by introducing point 
mutations into JoJ48C11, corroborating its correctness.
Results
Structure analysis of JoJ48C11 Fab and the JoJ48C11 Fab/laminarihexaose complex. In order 
to obtain detailed information about the binding of SCH and other β-(1,3)-branched β-(1,6)-D-glucans by 
JoJ48C11, we resorted to an X-ray crystallographic structure analysis. For this, we produced recombinant Fab 
fragments of JoJ48C11 by adding human constant CH1 and Ckappa domains to the respective variable regions of the 
initial JoJ48C11 scFv fragment and crystallized the purified protein to collect diffraction data.
Initial phasing of the JoJ48C11 Fab fragment was performed by molecular replacement with the structure of 
a chimeric antibody Fab fragment against CD25 (PDB entry 1MIM) as a search model27. The resulting structure 
was refined to 3.0 Å resolution. The JoJ48C11 Fab fragment adopts the expected heterodimeric structure of a 
heavy chain fragment and a light chain both consisting of a constant (C) and a variable (V) immunoglobulin 
(Ig) domain. The Ig domains show the typical immunoglobulin fold characterized by two anti-parallel β-sheets 
packed against each other (Fig. 1a)28. Not surprisingly, backbone atoms can easily be superposed onto other Fab 
structures, and even several structures with almost identical CL, CH and VL domains including their CDRs can be 
found (Table 1). However, with respect to previously published Fab fragments, the VH domain of JoJ48C11 Fab is 
slightly different, especially in the CDR3 region (Fig. 1b,c).
For understanding of the molecular determinants that contribute to the recognition of SCH by JoJ48C11, we 
aimed at obtaining the crystal structure of a complex with SCH but failed despite extensive attempts. Therefore, 
we resorted to structure determination of a complex with the less complex oligosaccharide laminarihexaose, 
which is a β-(1,3)-linked unbranched glucose hexamer. Electron density for two glucose moieties was observed 
when crystals were soaked with high concentration of the ligand (50 mM laminarihexaose) for one week. 
Interestingly, laminarihexaose does not show binding to JoJ48C11 in an in vitro affinity assay23, indicating that 
this is a good example for the sensitivity of protein crystallography to detect lower affinity29. The JoJ48C11 Fab/
laminarihexaose structure was refined to 2.4 Å resolution. In the complex, Asp105H of the heavy chain CDR3 
region binds the O4- and O6-atoms of the non-reducing end of laminarihexaose in a bidentate fashion (Fig. 2a 
and Supplementary Fig. S1). To confirm the observed interaction of Asp105H, we generated an alanine mutant 
and produced it as scFv-Fc. Binding of JoJ48C11-Asp105AlaH scFv-Fc to SCH was completely abrogated in a 
titration ELISA, which corroborates the importance of Asp105H and the significance of the JoJ48C11 Fab/lami-
narihexaose complex crystal structure.
The apo structure of JoJ48C11 Fab and the complex with laminarihexaose were used as template for modeling 
of JoJ48C11 Fab in complex with the triple helical SCH as described below.
Modelling the interaction of JoJ48C11 with triple helical SCH. To further refine insight into the 
JoJ48C11 Fab/SCH interaction, we used SwissDock to generate models of a complex with the repeating unit (RU) 
of SCH and the apo structure of JoJ48C11 Fab. 256 models in 44 clusters were generated and then inspected to 
select the most likely models for further analysis. Two similar docking poses positioning the RU inside the typical 
antigen binding area of antibodies were identified. They proposed that Trp33H, His35H, Trp47H, Tyr50H, Glu59H, 
Trp100H, Trp90L and Asn93L were interacting residues. Subsequent mutagenesis studies proved His35H, Trp47H, 
Trp100H and Trp90L to be necessary for binding SCH, since their respective alanine mutants showed significant 
decrease of binding strength with EC50 values of 1.1 nM to 10.9 nM, which are higher than 0.6 nM (3 times the 
EC50 value of wild type JoJ48C11 scFv-Fc). It is important to note that the main interaction sites predicted by 
docking are different from the position identified in the crystal structure with laminarihexaose, suggesting that 
JoJ48C11 may contain two separated recognition motives for β-(1-6)-linked glucose moieties (Fig. 2b).
With the information from the crystal complex and the docking poses with the RU of SCH, we aimed at gen-
erating a model of JoJ48C11 in complex with triple helical SCH. Interestingly, the binding sites for the terminal 
glucose moiety of laminarihexaose observed in the crystal structure and the second binding site identified by 
docking calculation are approx. 18 Å apart, which corresponds very well to the helix pitch distance of the SCH 
chains in the triple-helical form (Figs 2b and 3a)30. We therefore created a model of JoJ48C11 Fab in complex with 
triple-helical SCH by superimposing a SCH triple helix structure from the literature onto the β-(1,6)-linked glu-
cose unit of the docked SCH RU (Supplementary Fig. S2)31. To corroborate this model, we examined additional 
residues that are located close to the predicted binding sites of the triple-helical SCH, namely Tyr27H, Ser31H, 
Tyr57H, Asp49L, Lys52L and Ser55L, by generating respective alanine exchange mutants in the scFv-Fc format. 
This revealed Tyr27H, Asp49L and Lys52L to be significantly involved in binding of SCH, validating our structural 
model of the JoJ48C11 Fab/triple-helical SCH interaction (Fig. 3b and Table 2).
The model suggests that five glucose units are involved in binding to JoJ48C11: two β-(1,6)-linked moieties 
of SCH chain 1 fit into the two binding cavities found in the crystal structure with laminarihexaose and in the 
docking studies with the RU of SCH, one β-(1,6)-linked and one β-(1,3)-linked glucose group of SCH chain 2 
interact with VH and VL in the area between the two binding cavities, and one β-(1-3)-linked moiety of SCH 
chain 3 interacts with VL near the docking site of the RU of SCH. The distribution of torsion angles values at the 
β-(1,3)-glycosidic bonds of triple-helical SCH in the modeled complex with JoJ48C11 after energy minimization 
is very similar to values observed in crystal structures, indicating the high geometrical quality of the model 
(Supplementary Fig. S3). According to our binding studies, the antibody itself contributes eight amino acid res-
idues (Tyr27H, His35H, Trp47H, Trp100H, Asp105H; Asp49L, Lys52L, Trp90L) to this interaction, acting mainly 
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through hydrogen bonds or π-effects (Fig. 3c,d). Taken together, this provides an explanation for JoJ48C11’s 
specificity towards SCH triple helices.
Discussion
Basic characteristics for the paratope structure of carbohydrate binding antibodies were early established by stud-
ies of anti-dextran binding antibodies. They predicted that the respective antibodies consist of a cavity-shaped 
paratope for accommodation of terminal saccharide residues or of a groove structure for up to seven internal sac-
charide residues of a linear polysaccharide chain32,33. To date, the structures of a few anti-carbohydrate antibodies 
have been determined by X-Ray crystallography. They indeed show the predicted cavity or groove structures of 
their paratope and some even consist of a combined structure of both types34. To name one interesting example, 
the monoclonal antibody F22-4 that is directed against the O-Antigen (lipopolysaccharide) from serotype 2a 
Shigella flexneri consist of a groove-shaped paratope with two small cavities integrated. Co-crystallization with 
a synthetic fragment (decasaccharide) of the O-antigen clearly showed the binding-orientation of the helically 
bowed fragment along the groove with two branches of single glucose residues fitting into the small cavities35. 
Figure 1. Structure of JoJ48C11 Fab. (a) Overall structure of JoJ48C11 Fab. The colors for each chain are green 
and cyan for heavy chain and light chain, respectively. CDR-region on heavy chain and light chain shown as 
brown and magenta colors. Sticks indicate important amino acid residues for binding to triple-helical SCH. 
(b) Superposition of variable regions of the heavy chain of JoJ48C11 and previously published Fab fragments. 
The colors are green for JoJ48C11, and red, blue or yellow for an antibody against SPE7 (PDB entry 1OAQ), 
Fab316.1 (PDB entry 5D93) or 10D10 (PDB entry 5T5N), respectively. (c) Superposition of the variable regions 
of the light chain of JoJ48C11 and previously published Fab fragments. The colors are cyan for JoJ48C11, and 
red, blue or yellow for an antibody against TRAAK (PDB entry 4I9W), B7-H6 (PDB entry 4ZSO) or MFE-23 
(PDB entry 1QOK), respectively.
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For JoJ48C11 we stated that the combination of the triple helical structure with the protruding β-(1,6)-linked 
D-glucose is a crucial factor for binding23. Therefore, we expected a groove-shaped paratope for interchain recog-
nition of SCH with at least one cavity-shaped binding site to accommodate a β-(1,6)-linked D-glucose.
Here, we discovered via protein crystallography and in silico docking that the paratope structure of JoJ48C11 
consists of two cavity-shaped binding sites that are connected by a shallow groove. These cavities can accommo-
date single glucose residues and are approx. 18 Å apart, a distance that corresponds strikingly well to the helical 
pitch in structural models of triple-helical SCH30. This enabled us to generate a model of the JoJ48C11 Fab/SCH 
complex, which is defined by the protruding β-(1,6)-linked D-glucose residues positioned in the two cavities. 
Experimental validation by mutagenesis indicated that eight amino acids of JoJ48C11 predicted to be involved 
in binding of SCH, namely Tyr27H, His35H, Trp47H, Trp100H, Asp105H, Asp49L, Lys52L and Trp90L, are indeed 
required, confirming the correctness of the model.
The complete abrogation of binding by mutation of Asp105H reveals the critical function of this residue. As 
part of one of the two binding cavities, it was identified to engage in two hydrogen bonds with the glucose unit at 
the non-reducing end of laminarihexaose in the complex crystal structure. Such bidentate interactions between 
acidic residues and saccharide moieties are an important motif in protein/carbohydrate complexes36 and the 
model with SCH suggests that Asp105H contributes a similar interaction to a β-(1,6)-linked moiety from SCH 
chain 1.
In silico docking suggested that His35H, Trp47H, Trp100H and Trp90L establish walls around a second cavity 
for the binding of a second β-(1,6)-linked glucose moiety of SCH chain 1. Histidine and tryptophan are often 
found in carbohydrate binding sites, where they seem to interact through aromatic contacts36. Such interactions 
are known to determine the specificity of carbohydrate binding proteins, but their contribution to the stability of 
such complexes is rather modest37,38, which is in line with the observation that mutation of these residues led to 
a smaller affinity decrease than in the case of the Asp105AlaH substitution. However, the function of Trp47H and 
CL CH VL VH
PDB 
IDs Za rmsdb %idc PDBIDs Za rmsdb %idc
PDB 
IDs Za rmsdb %idc
PDB 
IDs Za rmsdb %idc
5ILD 21.1 0.4 99 5ITB 21.1 0.5 99 4I9W 23.4 0.4 96 1OAQ 23.3 1.2 84
5VH3 21.1 0.4 99 4HH9 21.1 0.5 100 4ZSO 23.2 0.4 90 1OAU 23.2 1.1 84
4XMP 21.1 0.4 99 5U3M 21.1 0.5 99 1QOK 23.1 0.6 89 1OAR 23.1 1.2 84
4J6R 21.0 0.5 99 5IES 21.1 0.3 100 5D93 23.1 0.5 87 5D93 23.1 1.0 77
5TE7 21.0 0.5 99 5MVZ 21.1 0.5 99 2ZKH 23.1 0.5 83 2E27 23.1 0.8 78
5MVZ 21.0 0.5 99 4PUB 21.1 0.4 99 2W9D 23.1 0.6 93 5T5N 23.1 1.1 79
3QOS 21.0 0.4 99 1L7I 21.0 0.5 100 2Z91 23.0 0.5 92 3HNS 23.0 1.2 70
5DRX 21.0 0.4 99 5U3O 21.0 0.6 99 5D93 23.0 0.5 87 1SY6 23.0 1.0 89
5D6C 21.0 0.3 99 5U3N 21.0 0.5 99 4F33 23.0 0.6 90 3HNT 23.0 1.2 70
5IES 20.9 0.3 100 4IFY 20.9 0.7 100 4EBQ 23.0 0.6 83 1OAX 22.9 1.2 84
Table 1. Superposition of JoJ48C11 Fab on other Fab Cα-positions. The percent identities, rmsd values, 
and Z-scores have been calculated with DALI62 using the JoJ48C11 Fab as a reference (PDB entry 6EV1). aZ: 
Z-scores, DALI gives higher Z-scores for highly similar structures. brmsd: Root mean square deviation for 
superposition of Cα atoms. c%id: Percent identities.
Figure 2. Structural models of the binding between JoJ48C11 Fab and glucose moieties. (a) X-ray crystal 
structure of JoJ48C11 Fab complex involved in laminarihexaose. Glucose residues of laminarihexaose bound 
to JoJ48C11 Fab are shown as ball-and-sticks (gray) with mFo-DFc electron density map contoured at 2.5 σ. 
Dashed lines indicate potential hydrogen bonds. (b) Superposition of the laminarihexaose complex structure 
(gray) and the SCH RU binding model derived by docking calculations (yellow).
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Trp100H may extend beyond establishing aromatic contacts. As a conserved residue in frame work 2 of the VH 
domain, Trp47H seems to possess an additional structural role: Herold et al. observed that Trp47H contributes to 
the stability of the VH domain as well as to the VH/VL association in the antibodies MAK33 and 2A2 rheumatoid 
factor39. Trp100H, on the other hand, seems to involve the an additional hydrogen bond between the indole group 
and a β-(1,3)-glucose moiety of SCH chain 3. A similar interaction has also been observed by Cygler et al. for an 
antibody against polysaccharide O-antigen of pathogenic Salmonella of serogroup B40. Interestingly, in order to 
avoid clashes with SCH, Trp100H has to adopt a different sidechain rotamer than is observed the apo structure. 
The required conformation is found in two out of four copies of the laminarihexaose complex, however, which 
may be indicative of crosstalk between the two glucose binding sites (Supplementary Fig. S4).
The potential involvement of Tyr27H, Asp49L and Lys52L in SCH recognition was only discovered from the 
JoJ48C11/triple-helical SCH complex model. Tyr27L seems to interact with a β-(1,6)-bound glucose of SCH chain 
2, whereas Asp49L and Lys52L engage in hydrogen bonds with one β-(1,3)-bound glucose unit of the same SCH 
chain. Of these residues, Asp49L is especially important as can be concluded from the large decrease in binding 
affinity observed after its mutation to alanine (Fig. 3b).
Figure 3. Model of the complex between JoJ48C11 Fab and triple-helical SCH. (a) Overall view. The chains of 
SCH are colored black, blue and yellow, respectively for chain 1, 2 and 3. (b) Comparison of the calculated EC50 
values from the Binding assay with SCH and point mutants of JoJ48C11 in the scFv-Fc format. The dashed line 
at 0.6 nM marks the EC50 value considered to be the threshold for indicating a significant decrease in binding 
strength. (c) Surface model of JoJ48C11 Fab in complex with triple-helical SCH. The CDR-regions of the 
antigen binding site are shown in gray and thick ball-and-sticks indicate important glucose moieties interacting 
with JoJ48C11 Fab. (d) Close-up view of the triple-helical SCH binding site of JoJ48C11 Fab.
scFv-Fc EC50 [nM] scFv-Fc EC50 [nM]
JoJ48C11 0.22 ± 0.01 Glu59AlaH 0.52 ± 0.03
Trp27AlaH 0.86 ± 0.11 Trp100AlaH 10.94 ± 1.15
Ser31AlaH 0.22 ± 0.04 Asp105AlaH >>1000
Trp33AlaH 0.36 ± 0.08 Asp49AlaL 163.2 ± 9.5
His35AlaH 2.28 ± 0.17 Lys52AlaL 4.78 ± 0.26
Trp47AlaH 6.40 ± 1.17 Ser55AlaL 0.30 ± 0.06
Tyr50AlaH 0.30 ± 0.05 Trp90AlaL 1.07 ± 0.09
Tyr57AlaH 0.22 ± 0.02 Asn93AlaL 0.23 ± 0.02
Table 2. EC50 values from the Titration ELISA of JoJ48C11 scFv-Fc and its point mutants.
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In summary, we have determined the structure of the anti-SCH antibody JoJ48C11 and obtained further 
insight into SCH binding by combining crystal structure analysis of a complex with a molecule that does not show 
binding in ELISA experiments, in silico docking of a SCH RU and modeling of the JoJ48C11 Fab/triple-helical 
SCH complex by hand. The model is consistent with experimental data and validates our previous hypothesis 
about the specificity of JoJ48C11 towards SCH and other similar β-(1,6)-branched β-(1,3)-D-glucans, namely 
that the β-(1,6)-bound D-glucose residues in conjunction with the triple-helical structure constitute the binding 
epitope for the antibody JoJ48C1123. Our work provides first insight into the structural principles that govern the 
binding of triple-helical SCH to a SCH-specific antibody and provides another example of an anti-carbohydrate 
antibody structure in complex with its antigen.
Materials and Methods
Preparation of JoJ48C11 as Fab for crystallography. JoJ48C11 was produced as a Fab in HEK239–6E 
cells (National Research Council, Biotechnological Research Institute). Towards this, the DNA encoding VH 
and VL of JoJ48C11 scFv were cloned into the respective vectors pCSE2.5-Fab-k-His-XP and pCSE2.5-Fab-h-
His-XP23. A mixture containing 12.5 µg of both vectors was used for PEI-mediated transfection of 25 mL culture 
(about 1.5 × 106 cells mL−1). Transfection and production were carried out as described previously23,41. After 
production, the Fab was isolated by His-tag affinity purification. 1 mL of Chelating Sepharose Fast Flow (GE 
Healthcare) complexed with nickel was incubated with the cell free supernatant supplemented with 0.5 M NaCl. 
The sepharose was washed in a gravity flow column with 25 volumes of His-tag binding buffer (0.5 M NaCl, 
20 mM Na2HPO4, 20 mM NaH2PO4, 10 mM imidazole, pH 7.4) and the Fab was eluted in 2 mL 0.1 M EDTA in 
PBS (8.0 g L−1 NaCl, 0.2 g L−1 KCl, 1.44 g L−1 Na2HPO3*4 H2O, 0.24 g L−1 KH2PO4, pH 7.4). Possible agglom-
erates were removed by subsequent size exclusion chromatography. For this, the eluate of the His-tag affinity 
purification was loaded onto a Superdex 75 HiLoad 16/60 column (GE Healthcare) running at 0.75 mL min−1 
in crystallization buffer (20 mM Tris-HCl, 150 mM NaCl, pH 8.0). The resulting monodisperse Fab was concen-
trated to 7.2 mg mL−1 with Amicon Ultra – 0.5 mL Centrifugal Filters 30 K (Merck Millipore) and directly used 
for crystallization.
Crystallization and data collection. Initial crystallization experiments were carried out with a HoneyBee 
crystallization robot (Digilab) and 96-well sitting-drop Intelli-plates (Art Robbins Instruments) at 200 nL vol-
ume of protein and an equal volume of reservoir solution. Clusters of needle-shaped multicrystals growing from 
a single nucleation center were obtained at 20 °C with a precipitant containing 0.1 M Tris pH 8.5, 0.2 M lithium 
sulfate and 30% w/v PEG 4000. Crystals were washed in cryoprotectant (0.1 M Tris pH 8.5, 0.2 M lithium sul-
fate, 30% w/v PEG 4000 and 20% w/v glycerol) before flash-cooling in liquid nitrogen. A single needle was iso-
lated and a 3 Å data set was collected from two wedges at 100 K on beamline P11 of the PETRAIII-synchrotron 
at DESY (Hamburg, Germany), using a PILATUS 6M-F detector to merge 1800 and 400 0.1°-frames, respec-
tively. The crystal belonged to the monoclinic space group P21, with cell parameters of a = 94.03 Å, b = 112.86 Å, 
c = 140.82 Å and β = 98.62°. The asymmetric unit contained 6 copies of Fab fragment with a calculated Matthews 
parameter (VM) of 2.41 Å3/Da, corresponding to a solvent content of 48.9%.
For optimization of the crystallization, macroseeding was carried out with drops consisting of 500 nL protein 
solution, 600 nL precipitant (0.1 M HEPES pH 7.5, 0.1 M sodium acetate, 0.2 M lithium sulfate, 25% w/v PEG 
4000) and 100 nL macroseed crystal from 0.1 M Tris pH 8.5, 0.2 M lithium sulfate and 30% w/v PEG 4000, set 
up with an OryxNano crystallization robot (Douglas Instruments Ltd). Crystals were observed after 2 months 
and were soaked by adding 50 mM laminarihexaose to the drop for 1 week and subsequent flash freezing in 
liquid nitrogen without additional cryoprotectant. Diffraction data were collected from 3600 0.05°-oscillation 
images to a maximum resolution of 2.4 Å. The complex crystal belonged to space group P21 with cell parameters 
of a = 81.73 Å, b = 131.50 Å, c = 91.03 Å and β = 91.51°. The asymmetric unit contained 4 copies of the Fab frag-
ment, with a calculated Matthews parameter (VM) of 2.39 Å3/Da (solvent content 48.5%). Diffraction data were 
processed and scaled using autoPROC with XDS, pointless and aimless42–46. Statistics for the data collection are 
described in Table 3.
Structure determination and refinement. The structure of the anti-SCH JoJ48C11 Fab was solved by 
the automated molecular replacement pipeline BALBES (https://www.ccp4.ac.uk/ccp4online/), using the struc-
ture of a Fab fragment of a chimeric antibody against CD25 (PDB entry 1MIM) as a search model27. The complex 
structure with laminarihexaose was solved by molecular replacement with PHASER as included in the PHENIX 
software suite using the apo structure of JoJ48C11 Fab as a search model47,48. An initial atomic model was man-
ually improved using COOT and refined with PHENIX and REFMAC by standard protocols49,50. Refinement 
statistics for the JoJ48C11 Fab fragment structures are summarized in Table 3. Coordinates and structure fac-
tors have been deposited in the Protein Data Bank (PDB) with accession codes 6EV1 (JoJ48C11 Fab) and 6EV2 
(JoJ48C11 Fab:laminarihexaose complex)51. Figures were prepared using PYMOL52.
Molecular modeling. Molecular docking calculations were performed using the SwissDock web service 
(http://swissdock.vital-it.ch/) with default parameters and settings53,54. The variable region of the apo structure of 
JoJ48C11 Fab (residue 1 to 116 of chain A (VH) and 1 to 106 of chain B (VL)) was selected as the target. Water mol-
ecules were removed from the structure. For the ligand, a three-dimensional model of the SCH RU was obtained 
from the PubChem Compound Database (CID:24777) and was converted into MOL2 file format using YASARA 
View55,56. Results were visualized with the UCSF Chimera package and unique docking poses were selected by 
visual inspection57.
To derive a model for the interaction of JoJ48C11 with triple-helical SCH, the selected docking pose of the 
SCH RU was superposed onto chain A and B of the laminarihexaose complex. Residues Leu99 to Asp105 of chain 
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A and Lys44 to Val57 as well as Gln89 to Asn93 of chain B were replaced with the corresponding residues from 
chain A and B of the apo structure due to the fact that Trp100 of chain A and Asp49 and Trp90 of chain B adopted 
different sidechain rotamers than in the apo structure that had been used for the docking calculations with SCH 
RU. The model of triple-helical SCH was generated using a structure of the triple-helical curdlan as a template 
(http://polysac3db.cermav.cnrs.fr/polysacdb/curdlan-II/curdlan2_3chains_expanded.pdb in PolySac3DB), 
which was modified into triple-helical SCH by manually adding β-(1,6)-bound glucose moieties homogenously 
at every third glucose moiety of each chain58,59. Subsequently, triple-helical SCH was fitted onto the JoJ48C11 
Fab structure by visual superposition of two β-(1,6)-bound glucose with the two glucose moieties from the com-
plex structure with laminarihexaose and the docking model with SCH RU. Subsequently, the two β-(1,6)-bound 
glucose of triple-helical SCH used for the superposition were replaced with the two glucose moieties from the 
laminarihexaose complex and the SCH RU docking pose. Finally, energy minimization was performed with the 
YASARA Energy Minimization Server (http://www.yasara.org/minimizationserver.htm)60. The complete docking 
and modeling procedure is summarized in Supplementary Fig. S1.
Generation and preparation of JoJ48C11 mutants as scFv-Fc. The mutants of JoJ48C11 variable 
chains for the binding studies were derived by quick change PCR for site directed mutagenesis61. PCR experiments 
were conducted with Phusion® High Fidelity DNA Polymerase (Thermo Fisher Scientific). Primer pairs were 
designed for each mutation site with the mismatch alanine codon framed by at least six bases in the 5′-direction 
JoJ48C11 Fab JoJ48C11 Fab + laminarihexaose
Data collection
X-ray sourcesa P11, DESY P11, DESY
Space group P21 P21
Cell dimensions
a, b, c (Å) 94.08 112.83 140.82 81.73 131.50 91.03
α, β, γ (°) 90.00, 98.61, 90.00 90.00, 91.50, 90.00
No. of subunits/ASUb 6 4
Wavelength (Å) 1.03320 1.03320
Resolution (Å) 3.04 (3.096–3.043)c 2.40 (2.445–2.403)c
Total number of observation 188636 (9678) 516202 (26154)
Total number unique 55718 (2768) 74793 (3694)
Rsym (%)d 13.0 (64.7) 9.6 (77.9)
Rmeas or Rr.i.m. (%)e 15.5 (76.4) 10.3 (84.0)
Rpim (%)f 8.3 (40.4) 3.9 (31.2)
Mean(I)/sd(I) 8.9 (2.2) 12.9 (2.2)
Completeness (%) 99.4 (99.3) 100.0 (99.6)
Multiplicity 3.4 (3.5) 6.9 (7.1)
Refinement
Resolution range (Å) 56.416–3.043 55.787–2.403
Reflections used 55674 74686










Bond length (Å) 0.004 0.004
Bond angles (°) 1.003 0.756
Ramachandran outliers (%) 0.08 0.23
PDB ID 6EV1 6EV2
Table 3. Data collection and refinement statistics. aDESY: German Electron Synchrotron, Germany. bASU; 
Asymmetric Unit. cValues in parentheses are for reflections in the highest resolution bin. dRsym = ΣhΣi|I(h,i) 
− <I(h)> |/ΣhΣi I(h,i), where I(h,i) is the intensity of the ith measurement of reflection h and <I(h)> is the 
corresponding average value for all i measurements. eRmeas = Rr.i.m. (redundancy-independent merging 
R-factor) = Σh[N/(N − 1)]1/2Σi(|Ii(h) − <I(h)> |)/ΣhΣiIi(h) fRp.i.m. (precision-indicating merging R-factor) = Σh[1/
(N − 1)]1/2Σi(|Ii(h) − <I(h)>|)/ΣhΣiIi(h). gRwork = Σ||Fo| − |Fc||/Σ|Fo|, where Rfree is calculated for the 5% test set of 
reflections.
www.nature.com/scientificreports/
8SCIentIfIC RepoRtS |  (2018) 8:13652  | DOI:10.1038/s41598-018-31961-x
and thirteen bases in the 3′-direction. The mutated scFv DNA sequence was cloned into pCSE2.6-mIgG2c-Fc-XP 
vector and used for transfection of HEK cells (EXPI293-F™, Thermo Fisher Scientific)41. The cells were culti-
vated as described above. For transfection, 5 µg of the vector DNA was added to 250 µL culture medium and 
mixed with 250 µL medium containing 25 µg polyethylenimine. 5 mL of cells (ca. 1.5 × 106 cells mL−1) were trans-
ferred into 40 mL screw cap tubes (Sarstedt), the DNA-PEI mixture was added and the culture was incubated at 
37 °C, 190 rpm as well as 5% CO2 in the atmosphere (HERAcell™, Thermo Fisher Scientific and Celltron, Infors). 
48 h after transfection the culture was fed with 5 mL HEK TF medium (Xell AG) supplemented by 8 mmol L−1 
L-glutamine and 1 mL of HEK FS medium (Xell AG). The scFv-Fc mutants were isolated by protein A affinity 
purification. 9.5 ml of cell free supernatant was incubated with 500 µL of protein A purification resin (MabSelect™ 
SuRe™, GE Healthcare). The loaded resin was washed with 20 volumes PBS and the scFv-Fc was eluted in 2 mL 
of 100 mM citrate puffer (pH 3). For pH neutralization, 220 µL of 1 M Tris was added immediately after elu-
tion. Afterwards the buffer was exchanged for PBS by centrifugation with Zeba™ desalt spin columns (Thermo 
Fisher Scientific). The concentrations of the antibody preparations were calculated by their absorbance at 280 nm 
(NanoDrop 2000, Thermo Fisher Scientific).
Titration ELISA. Titration ELISA (enzyme-linked immunosorbent assay) was performed on Carbo-BIND™ 
multiwell plates (Corning) loaded with proteinase K-treated SCH (SCH-PK) as described before23. Briefly, serial 
dilutions of the scFv-Fc antibodies ranging from 0.03 pM to 950 nM were prepared in blocking solution (2% w/v 
milk powder and 0.05% w/v Tween® 20 in PBS) and added to the blocked multiwell plates (100 µL per well). After 
1 hour incubation, the plates were washed 3 times with PBST (0.05% w/v Tween® 20 in PBS). For the titration of 
the point mutants in the scFv-Fc format, the plates were incubated with peroxidase-conjugated goat anti-murine 
Fc antibody (A0168, Sigma-Aldrich, 1:40,000 in blocking solution, 100 µL per well). For Detection of JoJ48C11 
in the Fab format, the plates were first incubated with a mouse anti-His-tag antibody (DIA-900, Dianova, 100 µL 
per well, 40 ng ml−1) before incubation with the peroxidase-conjugated antibody. The ELISA was developed by 
adding 100 µL TMB solution (20 volumes 30 mM potassium citrate, 0.5 M citric acid, pH 4.1 and 1 volume 10 mM 
3,3′,5,5′-tetramethylbenzidine, 10% v/v acetone, 90% v/v ethanol, 0.3% v/v H2O2)) per well. The color reaction 
was stopped after 10 minutes by addition of 100 µL of 0.5 M H2SO4 per well. The resulting absorption was meas-
ured at 450 nm (reference wavelength 620 nm). Each mutant was investigated in three independent experiments.
The datasets generated during and/or analyzed during the current study are available from the corresponding 
author on reasonable request.
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